The birth and rise of a craniopharyngioma: the radiological evolution of an incidental craniopharyngioma detected on serial MRI during medical treatment of a macroprolactinoma by Mariotti, Stefano et al.
CASE REPORT
The birth and rise of a craniopharyngioma: the radiological
evolution of an incidental craniopharyngioma detected on
serial MRI during medical treatment of a
macroprolactinoma
Stefano Mariotti1, Marco Losa2, Pietro Mortini2 & Luca Saba3
1Endocrinology, Department of Medical Sciences, University of Cagliari, Cagliari, Italy
2Department of Neurosurgery, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy
3Radiology, Department of Medical Sciences, University of Cagliari, Cagliari, Italy
Correspondence
Luca Saba, Radiology, Department of Medical
Sciences, University of Cagliari, Cagliari,
09100 Italy. Tel:/Fax: 0706753193;
E-mail: lucasaba@tiscali.it
Funding Information
No sources of funding were declared for this
study.
Received: 11 October 2015; Revised: 21
March 2016; Accepted: 3 May 2016
doi: 10.1002/ccr3.623
Key Clinical Message
This case demonstrates the rare coexistence of a prolactinoma with cranio-
pharyngioma and documents its radiological growth. This case suggests that
patients with pituitary neoplasms should be followed closely and although pro-
lactinomas can often be managed medically, a coexistent other lesion may
require surgery for histological assessment and to reduce mass effect.
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We would like to present the case of a 38-year-old female
patient with amenorrhea, galactorrhea, and marked
hyperprolactinemia discovered few months ago, with a
giant macroprolactinoma and the unusual finding of an
almost synchronous rise of a craniopharyngioma, during
the progressive shrinking of the pituitary tumor on caber-
goline therapy. Thus, in this patient, two uncommon
conditions occurred: firstly, the sequence of the “birth” of
a craniopharyngioma and secondly, the presence of two
sellar lesions at the same time.
Five Magnetic Resonance Imaging (MRI) exams were
performed and all the procedures were acquired on a
Gyroscan 1.5-T superconducting magnet (Philips, Best,
the Netherlands) with a head coil before and after the
administration of 6 mL of contrast material (gadolinium,
Gadovist, Bayer-Schering, Leverkusen, Germany).
The patient underwent the first MRI for amenorrhea
(performed 6 months earlier, after interruption of com-
bined estrogen-progestin pill), galactorrhea, and marked
hyperprolactinemia (>318,000 mIU/L [>15,000 ng/mL],
normal values in our Laboratory: <424 mIU/L [<20 ng/
mL] in women and <318 mIU/L [<15 ng/mL] in men).
No other abnormalities of anterior and posterior pituitary
hormone secretion were documented. The patient
reported mild cephalalgia since several years (for which
no specific investigation was performed), a computerized
campimetry was normal and no other visual defects were
present. A big (61 9 53 mm) mass with homogenous
hyper-signal after the intravenous administration of con-
trast material was documented in the sellar area, includ-
ing the caudal part of the infundibular stalk, without
involvement of the optic chiasm (Fig. 1A). A complete
encasement of the internal carotid artery was also present
with cavernous sinus invasion. These MRI features,
together with the clinical presentation and the prolactin
levels, were indicative for macroprolactinoma and accord-
ing to current guidelines, [1] the patient started cabergo-
line, 1.5 mg/week. In the second MRI exam performed
after 2 months, serum PRL was 1490 mIU/L (70.3 ng/
mL), galactorrhea disappeared and a reduction in the
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volume of the prolactinoma was clearly visible (Fig. 1B);
two months after, normal menses reappeared. From the
third exam (performed after 7 months), besides further
progressive reduction in the prolactinoma (serum PRL
496.1 mUI/L [23.4 ng/mL]), MRI revealed, in the
infundibular stalk, a small round lesion with a homoge-
nous hypointense signal on T1 sequences and enhanced
peripherally after gadolinium; these are typical MRI fea-
tures associated with a craniopharyngioma (Fig. 1C).
During the two following MRI checks (14 months and
22 months), the stalk mass becomes larger reaching a
diameter of 15.6 mm (from a value of 3.2 mm) with cra-
nial dislocation of the optic chiasm (Fig. 1D and E).
Indeed, the last MRI was performed 4 months in advance
for the sudden appearance about 3 weeks before of anim-
portant visual field defect, which was confirmed by com-
puterized campimetry. Further reduction in the
prolactinoma size was observed, while serum PRL was
207.8 mIU/L (9.8 ng/mL). Moreover, the patient had
regular menses and no clinical/biochemical evidence of
anterior or posterior pituitary failure. The patient under-
went surgical procedure (by transphenoidal approach)
that confirmed the diagnosis of craniopharyngioma (his-
tological examination: papillary craniopharyngioma,
Grade I WHO). The surgery was followed by anterior
panhypopituitarism and central diabetes insipidus, requir-
ing adequate substitution therapy with hydrocortisone,
levothyroxine, estrogen-progestin pill, growth hormone,
and desmopressin. Since no specific effort was made to
remove the prolactinoma (very small and barely detect-
able at the time of transphenoidal surgery), the patient
was kept on cabergoline therapy, with serum prolactin
remaining <212 mIU/L (<10 ng/mL). Visual field
improved, but the recovery was not complete. The MRI
check performed 2 months after the surgical procedure
(Fig. 1D and F) did not find any evidence of recurrence
for both craniopharyngioma and prolactinoma, but
showed a herniation of the chiasmatic cistern into the
(A) (B) (C)
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Figure 1. Magnetic Resonance (MRI) coronal image TSE - T1-weighted after administration of contrast material. In panel A, B, C, D, and E the
images acquired in the first exam, after 2 months, after 7 months, after 14 months, and after 22 months, respectively, are given. The asterisks
identify the carotid arteries in the supra-clinoid segment. In panel A, the caudal part of the infundibular stalk (white arrow) seems to be involved
by the prolactinoma, whereas the optic chiasm does not show pathological signal (white arrowhead). There is also a complete encasement of the
internal carotid artery. In the panel B, the infundibular stalk (white open arrow) does not show alteration, whereas in the panel C, a small (mm
3.2) hypointense mass with peripheral enhancement is observed; these are the typical features of a craniopharyngioma that become clearer in the
panel D with a mass diameter of 5.7 mm and panel E with a mass diameter of 15.6 mm. In the panel E, the cranial dislocation of the optic
chiasm is also visible (white open arrowhead). In the MRI check, acquired 2 months after the surgical procedure, there was no evidence of
recurrence of pathology (panel F) but the herniation of the chiasmatic cistern into the sellar cavity is visible (white dashed line).
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sellar cavity, which could be responsible for the incom-
plete recovery of visual field.
Prolactinomas make up the majority of pituitary
macroadenomas and are fortunately often responsive to
medical management [2], as documented in the present
case. In cases where the tumor is refractory to medical
management, surgical resection is necessary [3]; since
refractoriness to medical therapy is more frequent in giant
prolactinomas (as the tumor of the present report) which
may require multimodal therapy [4], we performed fre-
quent MRIs to strictly follow the tumor morphology;
however, the response to cabergoline therapy in terms of
reduction in tumor mass, prolactin secretion, and clinical
symptoms was excellent.
Magnetic resonance imaging is considered the imaging
technique of choice in pituitary and para-sellar tumors
because it accurately depicts the complex anatomy around
the sellar well [5]. Several pathologic entities occur in this
region, and most can be differentiated with MRI. These
entities can be broadly divided on the basis of their
involvement, as follows: intra-sellar, infundibular, supra-
sellar, anterior part of the third ventricle and/or optic chi-
asm, and sphenoid and/or cavernous sinus.
In this case, the extremely uncommon finding was the
opportunity to identify the birth and rise of a cranio-
pharyngioma, during the follow-up of a macroprolacti-
noma responding to cabergoline therapy. Moreover, a
second uncommon condition was documented: the pres-
ence of two different sellar lesions (prolactinoma and
craniopharyngioma) at the same time. This extremely
uncommon condition was probably responsible for the
delayed recognition of the craniopharyngioma image,
which was detectable several months before the onset of
visual field loss (Fig. 1C and D) and whose detection
could have allowed earlier surgical removal.
Finally, we considered the possibility that the appear-
ance of the craniopharyngioma could be the consequence
of cabergoline therapy, but we feel it very unlikely,
because until now no association has been described
between this drug and development of craniopharyn-
gioma.
Craniopharyngiomas are a benign but aggressive neo-
plasms arising along the craniopharyngeal duct. MRI fea-
tures suggest this pathological entity even if false-positive
results may occur with cysts, metastases, infarctions, epi-
dermoid cysts, and abscesses. All these lesions may appear
as areas of low-signal intensity after the administration of
gadolinium-based contrast agent, but the rim enhance-
ment is more likely associated with the craniopharyn-
gioma [6].
Some authors found that patients with craniopharyn-
gioma occasionally also have prolactinomas and in 1986
Wheatley et al. described the case of a 61-year-old man
using the CT image [7]. In a recently published review
paper, Guaraldi et al. reported that the association
between craniopharyngioma (typically adamantinomatous
type) and pituitary adenoma is very rare [8] but this
condition can occur and therefore, it is important to
strictly follow imaging techniques of patients with pitu-
itary tumors in order to identify the occurrence of a sec-
ond neoplasm. Aside from these sporadic reports, to the
best of our knowledge, no condition has been identified
so far with a clear association between prolactinomas
and craniopharyngiomas. Given the relatively young age
of the patient, the possibility of a still unrecognized
genetic mutation in one of the transcription factors
involved in the Rathke pouch’s formation and in the
early anterior pituitary development can be envisaged,
although at the present time, this possibility remains
fully speculative.
However, in this case also the location of cranio-
pharyngioma is uncommon, because this tumor is fre-
quently identified in the supra-sellar region only when its
diameter is much bigger than one in our case. The obser-
vation of the pituitary stalk craniopharyngioma is unusual
because it is uncommon that this tumor may be diag-
nosed at such an early stage that it only involves the pitu-
itary stalk, before enlarging and extending to supra- or
para-sellar region [9].
From the MRI point of view, in the differential diagno-
sis setting, the primary tumors that can involve the pitu-
itary stalk include gliomas, metastases (usually from
breast and lung cancers), leukemia (chronic myelogenous
leukemia and acute myelogenous leukemia), lymphoma,
and benign tumors like meningioma. However, when a
patient develops a new pituitary stalk lesion, the physician
should be aware that not infrequently these are malignant
lesions and it is therefore often required to intervene sur-
gically to obtain definitive histology [10].
The present case suggests that physicians should be
alerted to incidental diagnoses and that there is the need
for follow-up imaging and although prolactinomas can
often be managed medically, a coexistent other lesion
may require surgery for histological assessment and to
reduce mass effect.
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